lovastatin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors 1612 75330-75-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • lovastatin
  • lostatin
  • mevacor
A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.
  • Molecular weight: 404.55
  • Formula: C24H36O5
  • CLOGP: 4.08
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 72.83
  • ALOGS: -4.22
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
45 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.00 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.29 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 5 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Aug. 31, 1987 FDA MERCK

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 378.29 32.56 105 338 46538 2311104
Rhabdomyolysis 224.71 32.56 48 395 6656 2350986
Myalgia 220.66 32.56 60 383 23273 2334369
Completed suicide 156.48 32.56 45 398 20989 2336653
Myopathy 104.80 32.56 20 423 1523 2356119
Amyotrophic lateral sclerosis 77.41 32.56 12 431 261 2357381
Muscular weakness 71.99 32.56 23 420 14874 2342768
Muscle spasms 56.20 32.56 21 422 21545 2336097
Toxicity to various agents 50.98 32.56 22 421 32732 2324910
Asthenia 46.39 32.56 23 420 46903 2310739
Pain in extremity 39.49 32.56 20 423 42520 2315122
Gait disturbance 37.82 32.56 16 427 22529 2335113

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Rhabdomyolysis 271.16 42.59 67 371 11023 1735320
Completed suicide 245.50 42.59 67 371 16245 1730098
Myalgia 210.56 42.59 59 379 15599 1730744
Blood creatine phosphokinase increased 153.79 42.59 41 397 8815 1737528
Drug hypersensitivity 127.82 42.59 40 398 15095 1731248
Drug interaction 103.77 42.59 40 398 27918 1718425
Myopathy 86.21 42.59 19 419 1794 1744549
Toxicity to various agents 81.24 42.59 34 404 29107 1717236
Muscular weakness 65.34 42.59 22 416 10227 1736116
Asthenia 59.87 42.59 29 409 34641 1711702
Muscle spasms 58.81 42.59 21 417 11600 1734743
Myositis 55.58 42.59 13 425 1590 1744753
Myasthenic syndrome 54.21 42.59 8 430 72 1746271
Aspartate aminotransferase increased 48.99 42.59 18 420 10738 1735605
Alanine aminotransferase increased 46.67 42.59 18 420 12260 1734083
Cardiac arrest 45.49 42.59 19 419 15911 1730432

Pharmacologic Action:

SourceCodeDescription
ATC C10AA02 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, PLAIN
HMG CoA reductase inhibitors
ATC C10BA01 CARDIOVASCULAR SYSTEM
LIPID MODIFYING AGENTS
LIPID MODIFYING AGENTS, COMBINATIONS
HMG CoA reductase inhibitors in combination with other lipid modifying agents
FDA EPC N0000175589 HMG-CoA Reductase Inhibitor
MeSH PA D000924 Anticholesteremic Agents
MeSH PA D000963 Antimetabolites
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D019161 Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA D000960 Hypolipidemic Agents
MeSH PA D057847 Lipid Regulating Agents
CHEBI has role CHEBI:50266 prodrug
CHEBI has role CHEBI:35821 anticholesteremic drug
CHEBI has role CHEBI:35610 antineoplastic agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hypercholesterolemia indication 13644009
Hyperlipidemia indication 55822004 DOID:1168
Arteriosclerotic vascular disease indication 72092001
Hypoalphalipoproteinemia indication 190785000
Familial hypercholesterolemia - heterozygous indication 238079002
Mixed hyperlipidemia indication 267434003
Hypertriglyceridemia indication 302870006
Myocardial Reinfarction Prevention indication
Slow Progression of Coronary Artery Disease indication
Primary Prevention of Coronary Heart Disease indication
Myocardial Infarction Prevention indication
Cerebrovascular accident off-label use 230690007
Prevention of Transient Ischemic Attacks off-label use
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Myocardial infarction contraindication 22298006 DOID:5844
Low blood pressure contraindication 45007003
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Gout contraindication 90560007 DOID:13189
Disorder of muscle contraindication 129565002 DOID:423
Liver function tests abnormal contraindication 166603001
Hemorrhagic cerebral infarction contraindication 230706003
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Rhabdomyolysis contraindication 240131006
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Surgical procedure contraindication 387713003
Acute coronary syndrome contraindication 394659003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Traumatic injury contraindication 417746004
Uncontrolled Epilepsy contraindication

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme INHIBITOR IC50 7.67 WOMBAT-PK CHEMBL
Sodium-dependent noradrenaline transporter Transporter Ki 5.06 DRUG MATRIX
Sodium-dependent dopamine transporter Transporter Ki 5.10 DRUG MATRIX
Adenosine receptor A1 GPCR Ki 4.81 DRUG MATRIX
Substance-K receptor GPCR Ki 5.03 DRUG MATRIX
Hydroxycarboxylic acid receptor 2 GPCR IC50 7.30 WOMBAT-PK
Hydroxycarboxylic acid receptor 3 GPCR IC50 6.53 WOMBAT-PK
Nuclear receptor subfamily 1 group I member 2 Nuclear hormone receptor AGONIST EC50 6 IUPHAR
Histone deacetylase 6 Enzyme IC50 4.79 CHEMBL
Leukocyte adhesion glycoprotein LFA-1 alpha Adhesion Kd 4.89 CHEMBL
Histone deacetylase 1 Enzyme IC50 4.92 CHEMBL
Histone deacetylase 2 Enzyme IC50 4.59 CHEMBL
Androgen receptor Transcription factor Ki 4.70 DRUG MATRIX
Acetylcholinesterase Enzyme Ki 5.57 CHEMBL
Cholinesterase Enzyme Ki 5.96 CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme IC50 8.52 CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase Enzyme IC50 7.57 CHEMBL
Acyl-CoA:cholesterol acyltransferase Unclassified IC50 4.77 CHEMBL

External reference:

IDSource
4019482 VUID
N0000147602 NUI
C0024027 UMLSCUI
D00359 KEGG_DRUG
386024001 SNOMEDCT_US
4019482 VANDF
42628 MMSL
6472 RXNORM
96303004 SNOMEDCT_US
4998 MMSL
d00280 MMSL
002063 NDDF
9LHU78OQFD UNII
6074 INN_ID
CHEMBL503 ChEMBL_ID
DB00227 DRUGBANK_ID
803 PDB_CHEM_ID
CHEBI:40303 CHEBI
D008148 MESH_DESCRIPTOR_UI
53232 PUBCHEM_CID
2739 IUPHAR_LIGAND_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-0576 TABLET 20 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-0926 TABLET 10 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0093-0928 TABLET 40 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0070 TABLET 10 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0072 TABLET 20 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0074 TABLET 40 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-5589 TABLET 20 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-6551 TABLET 40 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-6590 TABLET 10 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-7674 TABLET 10 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-7679 TABLET 20 mg ORAL ANDA 13 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-7685 TABLET 40 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-7690 TABLET 40 mg ORAL ANDA 13 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-8151 TABLET 20 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 0615-8152 TABLET 40 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 10544-235 TABLET 10 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 10544-241 TABLET 20 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 10544-242 TABLET 40 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 10544-246 TABLET 20 mg ORAL ANDA 11 sections
LOVASTATIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-311 TABLET 10 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 21695-534 TABLET 10 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 21695-535 TABLET 20 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 21695-536 TABLET 40 mg ORAL ANDA 11 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 33261-547 TABLET 10 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 33261-548 TABLET 20 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 33261-549 TABLET 40 mg ORAL ANDA 12 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 42254-025 TABLET 40 mg ORAL ANDA 13 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 42254-028 TABLET 20 mg ORAL ANDA 13 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 42254-106 TABLET 10 mg ORAL ANDA 13 sections
Lovastatin HUMAN PRESCRIPTION DRUG LABEL 1 43063-493 TABLET 10 mg ORAL ANDA 11 sections